rejuvant life tabs

New investor offers funding to healthy aging innovators

Latest articles

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...
Rejuvant

A fifth investor has joined UK Research and Innovation (UKRI), providing matched funding for top small innovators to develop ideas for healthy aging.

The new investor in the healthy aging innovation is London-based Nesta; describing themselves as an “impact investor”, Nesta works on three missions: a fairer start, a healthy life and a sustainable future.

Longevity.Technology: The British Government is a great believer in the role technology can play in improving healthcare in the UK. However, many innovative companies lack the scale to bring real innovation to market. UKRI’s healthy aging investment partnership aims to inject the required capital to help some of the most promising businesses bring their innovations to market; the partnership does this by combining government funding and private investment in business-led research and development, supporting innovators to produce products and services for healthy aging that can be adopted at scale. Vitally, the government contribution de-risks the private sector investment, allowing cutting edge innovation to prosper.

The latest investor addition brings the total funding available under the programme to £18 million of grant funding and £18 million of equity investment available.

Lorraine Morley from Allia
Dr Lorraine Morley, UK Lead / Advisor for AgeTech Accelerator

Small and medium-sized enterprises can apply through one of two new and three original investor partners. In addition to Nesta, these now include: 24 Haymarket, Barclays Ventures, Northstar Ventures and Legal and General.

 


 

“NESTA could be a particularly strong ally as they unite the social impact and traditional investment worlds and these two elements need to be aligned if the age tech and healthy ageing market is to thrive…”

 


 

Nesta’s Chief Investment Officer, Nathan Elstub, said: “We are delighted to be able to work with UKRI to co-invest in the next generation of companies developing new ways of solving the challenge of ageing well.

Elevant

“Their grant funding will enable us to support riskier, more cutting-edge approaches to this challenge and will be a perfect match for the patient capital in our impact investment work.”

George MacGinnis, Healthy Ageing Challenge Director at UKRI added: “Nesta’s investment in our partnership programme brings a new dimension to our portfolio with their mission to invest for good. This will broaden the opportunities available to support business growth.

“Nesta brings extensive experience of supporting social entrepreneurs to develop sustainable businesses that address some of the toughest challenges faced by an ageing society.”

We reached out to Dr Lorraine Morley, UK Lead / Advisor for AgeTech Accelerator and member of our own advisory panel for her take on the appointment.

Elevant

“I am really pleased to hear that NESTA has been selected by UKRI as the latest joint-funding partner to support exciting and cutting-edge age tech businesses,” Dr Morley told us. “NESTA could be a particularly strong ally as they unite the social impact and traditional investment worlds and these two elements need to be aligned if the age tech and healthy ageing market is to thrive”.

Image credit: blank76Pixabay and Dr Lorraine Morley

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

FOXO exclusively licenses epigenetic clocks from UCLA

FOXO Technologies' exclusive licence of epigenetic clocks PhenoAge and GrimAge from UCLA could be an insurance game-changer. FOXO Technologies Inc has announced the licence of...

Longevity investment: small sums behind big ideas

Sonia Arrison talks about her journey to becoming an early stage investor and what longevity means to her. While longevity is now seeing increasing interest...

ChromaDex and H&H announce Niagen supply agreement

H&H Group expands Swisse healthy aging product line into growing NAD+ space with Niagen from ChromaDex. Los Angeles-based ChromaDex has announced it entered into a strategic...
Supps report ad middle